• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Helios Dr. Horst Schmidt Kliniken Wiesbaden,Helios Kliniken

    EST. 1879
    1,102论文总数
    1.7万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1102)

    年份
    起
    –
    止
    排序
    1Individualized Mrna Vaccines Evoke Durable T Cell Immunity in Adjuvant TNBC
    U Sahin, M Schmidt, E Derhovanessian, A Cortini, I Vogler, T Omokoko, E Godehardt, S Attig, S Newrzela, J Grützner, N Bidmon, S Bolte,

    Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of 'ready-to-act' cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches.

    2026Nature(2026)引用:8
    引用
    AI阅读
    加入学术空间
    2ENGOT-ov62 - Reducing Chemotherapy Duration in High-Grade Advanced Ovarian Cancer: A Comparison of 3 Vs. 6 Cycles of Platinum-Based Chemotherapy Followed by Niraparib Maintenance in HRD-positive Patients
    Jalid Sehouli,Eva Roser,Robert Armbrust,Dario Zocholl, Jessica Nguyen, Jessika Goldmann,Katharina Leitner, Philipp Meyer-Wilmes,Michal Zikan,Beyhan Ataseven,Toon Van Gorp, Suzana Mittelstadt,
    2026INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2026)
    引用
    AI阅读
    加入学术空间
    3Alleinige Wächterlymphknotenbiopsie Der Lymphadenektomie Nicht Unterlegen
    Michael Eichbaum,Christine Eichbaum
    2026InFo Hämatologie + Onkologie(2026)
    引用
    AI阅读
    加入学术空间
    4(Bau-)Vergaberecht – Eine Praxisorientierte Einführung
    Jochen Fürmann
    2026
    引用
    AI阅读
    加入学术空间
    5Neue Therapieoption Bei Fortgeschrittenem Brustkrebs?
    Michael Eichbaum,Christine Eichbaum
    2026InFo Hämatologie + Onkologie(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1102 篇论文

    合作机构(100)

    美茵茨大学合作论文 34
    柏林夏里特大学医学院合作论文 23
    德国海德堡大学合作论文 22
    南安普顿大学医院 NHS 基金会信托合作论文 19
    科隆大学医院合作论文 19
    慕尼黑大学合作论文 19
    石勒苏益格-荷尔斯泰因大学医院合作论文 18
    卢旺天主教大学合作论文 17
    弗莱堡大学医学院合作论文 16
    法兰克福大学医院合作论文 15

    机构统计